World News
IN SHORT
Saturday, November 17, 2018

Channels
frontpage
world
entertainment
odd news
politics
science
technology
health
sports
business

Latest
Overview
world
entertainment
odd news
politics
science
technology
health
sports
business
AD
Roche takes on Loxo, Bayer in gene
JAY GORY, MANAGING EDITOR, science
Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area. The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany's Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. read more
Disclaimer: Chances are that this post was requested by an advertiser.

(Possibly) Related news

More in science